Interní Med. 2016; 18(4): 180-183 | DOI: 10.36290/int.2016.041
New drugs for sarcoidosis
- 1 Klinika plicních nemocí a tuberkulózy FN a UP Olomouc
- 2 Ústav imunologie FN a LF UP Olomouc
Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the presence of granulomatous inflammation
in the affected tissues. It may involve practically any organ, particularly the lungs, eyes and skin. Treatment of sarcoidosis requires
a multidisciplinary team approach. If not recognized early or not adequately treated, sarcoidosis may progress to a chronic stage
in up to one-third of patients; in extreme cases, it may lead to serious health problems or premature death. In case of typical pulmonary
manifestations, the condition is not very difficult to diagnose. Cooperation of many experts is necessary when looking for
extrapulmonary manifestations of this granulomatous disease. Based on the examination results, treatment should be indicated.
The aim is to discuss the principles of sarcoidosis treatment including the standards of care related to lung disease, by focusing
on currently recommended novel drugs.
Keywords: corticosteroids, corticosteroids sparing drugs, biological treatment
Published: September 1, 2016 Show citation
References
- Kolek V. Sarkoidóza - dosud nepoznaná (1). Interní medicína pro praxi 2007; 6: 276-279. Kolek V. Sarkoidóza - dosud nepoznaná (2). Interní medicína pro praxi 2007; 7-8: 310-313.
- American Thoracic Society/ European Respiratory Society. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of sarcoidosis and Other granulomatopus disease(WASOG) adopted by the ATS Board of Directors and the ERS Executive Commitee. Am J Respir Crit Care Med 1999; 160: 736-755.
- Baughman R, Teirstein A, Judson M, Rossman M, Yeager H Jr, Bresnitz E et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
Go to original source... 
Go to PubMed... - Loštáková V, Kolek V, Vašáková M. Sarkoidóza - doporučený postup diagnostiky, terapie a sledování vývoje onemocnění - str. č. 1, Standardy ČPFS - Sekce pro intersticiální plicní procesy. http://pneumologie.cz/odborne/doc/Sarkoidoza.doc (přístup 1. 3. 2016).
- Pietinalho A, Ohmichi M, Hirasawa M, et al. Familial sarcoidosis in Finland and Hokkaido, Japan: a comparative study. Respir Med. 1999; 93: 408-412. Go to original source... Go to PubMed...
- Rodrigues SC, Rocha NA, Lima MS, Arakaki JS, Coletta EN, Ferreira RG, Gonzaga LR, Pereira CA. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 34-43.
- Baughman R, Winget D, Lower E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66.
- Belkhou A, Younsi R, El Bouchti I, El Hassani S, Younsi, El Bouchti, El Hassani (July 2008). "Rituximab as a treatment alternative in sarcoidosis". Joint, Bone, Spine 75(4): 511-512. Go to original source... Go to PubMed...
- Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches 2015; 3(10): 813-822. Go to original source... Go to PubMed...
- Hoyle C, Dawson J, Mather G. Treatment of pulmonary sarcoidosis with streptomycin and cortisone. Lancet 1955; 1: 638-643. Go to original source... Go to PubMed...
- Brun J, Kofman J, Faivre JM. Le traitement corticonique de le sarcoidose médiastinopuilmonaire: necessité d'un traitement précoce et place de I A.C.T.H. terapie (d apreś un bilan de 75 observations). Poumon Coeur. 1972; 28: 321-324.
- Votava V. Sarkoidóza. Avicenum, Praha 1985: 128.
- Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest 1985; 79: 27-36. Go to original source... Go to PubMed...
- llerdal G, Nöu E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984; 130: 29-32.
- Amin EN, Closser DR, Crouser ED. Current best practice in the management of pulmonary and systemic sarcoidosis. Ther Adv Respir Dis 2014; 8: 111-132. Go to original source... Go to PubMed...
- Baughman RP, Nunes H, Sweiss N, Lower E. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41: 1424-1438. Go to original source... Go to PubMed...
- Baughman RP, Shipley R, Desai S, Drent M, Judson M, Costabel U, et al. (2009b). Changes in chest rentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 136: 526-535. Go to original source... Go to PubMed...
- Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JP, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307. Go to original source... Go to PubMed...
- Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarc Vasc Diff Lung Dis. 2004; 21:43-48.
- Baughman RP, Judson MA, Costabel U, et al. Randomised, double blind, placebo controllled trial of infliximab in patiens with chronic pulmonary sarcoidosis. Chest. 2005; 128: 202S. Go to original source... Go to PubMed...